The results of this study provide rationale for the selection of MDM2 and MDM4 as therapeutic targets in cancer cells expressing wt TP53. MDM4 expression in wt TP53-tumors is a potential indicator for TP53 reactivation by combined MDM4 and MDM2-targeted cancer therapy. This evidence concerns the gene TP53 and cancer.